Results of a Phase 3 Study of Pembrolizumab Versus Best Supportive Care for Second-Line Therapy in Advanced Hepatocellular Carcinoma: KEYNOTE-240

Multicentric Prospective Study Of Validation Of Angiogenesis-Related Gene Polymorphisms In Hepatocellular Carcinoma Patients Treated With Sorafenib: Final Results Of Innovate Study

Alpha-fetoprotein (AFP) response and efficacy outcomes in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)

First-in-human, first-in-class phase I trial of MTL-CEBPA, a RNA oligonucleotide Targeting the Transcription Factor C/EBP-α, Given as a Single Agent or in Combination with Sorafenib, in Patients with Advanced Hepatocellular Cancer (HCC)

CHECKMATE 040: HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) AND CHILD-PUGH B STATUS TREATED WITH NIVOLUMAB (NIVO)

Safety Profile of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination Therapy in Patients (pts) With Advanced Hepatocellular Carcinoma (HCC) in the CheckMate 040 Study

Randomized, Open-Label, Perioperative Phase II Study Evaluating Nivolumab Alone or Nivolumab Plus Ipilimumab in Patients with Resectable HCC

Phase Ib Study Results: Safety and Efficacy of Atezolizumab + Bevacizumab Versus Atezolizumab in Patients with Previously Untreated, Unresectable or Advanced

A PHASE 3; RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF TRANSARTERIAL CHEMOEMBOLIZATION COMBINED WITH DURVALUMAB OR DURVALUMAB PLUS BEVACIZUMAB THERAPY IN PATIENTS WITH LOCOREGIONAL HEPATOCELLULAR CARCINOMA (HCC): EMERALD-1

The Safety and Efficacy of Namodenoson in the Second Line Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients with Underlying Child-Pugh B (CPB) Liver Cirrhosis: A Phase 2; Randomized, Double-Blind, Placebo-Controlled

ALPHA-FETOPROTEIN (AFP) RESPONSE AND OUTCOMES IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH REGORAFENIB OR PLACEBO IN THE PHASE 3 RESORCE TRIAL

MATCHING-ADJUSTED INDIRECT COMPARISON OF CABOZANTINIB VERSUS REGORAFENIB IN ADVANCED HEPATOCELLULAR CARCINOMA

SAFETY AND EFFICACY OF 12 MG/D LENVATINIB (LEN) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC) AND BODYWEIGHT (BW) >80 KG IN REFLECT

MULTICENTER PHASE II STUDY OF STEREOTACTIC ABLATIVE RADIOTHERAPY FOR HEPATOCELLULAR CARCINOMA ≤ 5 CM (KROG 12-02)

LIQUID BIOPSY FOR HEPATOCELLULAR CARCINOMA: POTENTIAL USEFULNESS OF MASSIVE SEQUENCING OF CIRCULATING DNA AS A TOOL FOR DIAGNOSIS AND FOLLOW-UP OF HCC PATIENTS